Private Wealth Partners LLC Purchases 5,930 Shares of Johnson & Johnson (NYSE:JNJ)

Private Wealth Partners LLC lifted its stake in Johnson & Johnson (NYSE:JNJ) by 8.7% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 74,330 shares of the company’s stock after purchasing an additional 5,930 shares during the period. Johnson & Johnson accounts for approximately 1.0% of Private Wealth Partners LLC’s holdings, making the stock its 28th largest holding. Private Wealth Partners LLC’s holdings in Johnson & Johnson were worth $11,650,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in the stock. Addison Advisors LLC boosted its position in shares of Johnson & Johnson by 5.9% in the 4th quarter. Addison Advisors LLC now owns 8,903 shares of the company’s stock worth $1,395,000 after purchasing an additional 494 shares during the last quarter. Gilliland Jeter Wealth Management LLC bought a new position in shares of Johnson & Johnson in the 4th quarter worth $2,467,000. Citizens Financial Group Inc. RI boosted its position in shares of Johnson & Johnson by 4.8% in the 4th quarter. Citizens Financial Group Inc. RI now owns 107,589 shares of the company’s stock worth $16,863,000 after purchasing an additional 4,954 shares during the last quarter. Heritage Financial Services LLC boosted its position in shares of Johnson & Johnson by 1.8% in the 4th quarter. Heritage Financial Services LLC now owns 10,269 shares of the company’s stock worth $1,609,000 after purchasing an additional 177 shares during the last quarter. Finally, Alesco Advisors LLC boosted its position in shares of Johnson & Johnson by 1.4% in the 4th quarter. Alesco Advisors LLC now owns 5,459 shares of the company’s stock worth $856,000 after purchasing an additional 76 shares during the last quarter. 69.55% of the stock is currently owned by institutional investors.

Insider Activity at Johnson & Johnson

In related news, major shareholder & Johnson Johnson sold 3,725 shares of Johnson & Johnson stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $25.81, for a total value of $96,142.25. Following the sale, the insider now owns 4,099,575 shares of the company’s stock, valued at $105,810,030.75. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In related news, major shareholder & Johnson Johnson sold 3,725 shares of Johnson & Johnson stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $25.81, for a total transaction of $96,142.25. Following the completion of the transaction, the insider now owns 4,099,575 shares in the company, valued at $105,810,030.75. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Jennifer L. Taubert sold 59,397 shares of Johnson & Johnson stock in a transaction dated Friday, February 9th. The stock was sold at an average price of $156.27, for a total value of $9,281,969.19. Following the transaction, the executive vice president now owns 141,416 shares of the company’s stock, valued at approximately $22,099,078.32. The disclosure for this sale can be found here. 0.16% of the stock is owned by company insiders.

Johnson & Johnson Price Performance

NYSE:JNJ opened at $151.16 on Thursday. The company has a debt-to-equity ratio of 0.38, a quick ratio of 0.91 and a current ratio of 1.16. The stock’s 50-day simple moving average is $154.65 and its 200 day simple moving average is $155.11. The company has a market cap of $364.26 billion, a P/E ratio of 9.42, a P/E/G ratio of 2.38 and a beta of 0.55. Johnson & Johnson has a 52-week low of $143.13 and a 52-week high of $175.97.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Tuesday, April 16th. The company reported $2.71 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.64 by $0.07. The business had revenue of $21.38 billion for the quarter, compared to the consensus estimate of $21.39 billion. Johnson & Johnson had a return on equity of 36.43% and a net margin of 45.26%. Johnson & Johnson’s quarterly revenue was up 2.3% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.68 earnings per share. As a group, sell-side analysts forecast that Johnson & Johnson will post 10.65 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 4th. Investors of record on Tuesday, May 21st will be given a $1.24 dividend. The ex-dividend date of this dividend is Monday, May 20th. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.28%. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.19. Johnson & Johnson’s payout ratio is currently 29.68%.

Analyst Upgrades and Downgrades

Several analysts recently commented on the company. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $215.00 price objective on shares of Johnson & Johnson in a research note on Monday, April 15th. Bank of America dropped their price objective on Johnson & Johnson from $180.00 to $170.00 and set a “neutral” rating on the stock in a research note on Wednesday, April 17th. Royal Bank of Canada dropped their price objective on Johnson & Johnson from $181.00 to $175.00 and set an “outperform” rating on the stock in a research note on Wednesday, April 17th. Morgan Stanley dropped their price objective on Johnson & Johnson from $168.00 to $167.00 and set an “equal weight” rating on the stock in a research note on Wednesday, April 17th. Finally, StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, February 6th. Seven analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $175.86.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.